Pharming Group N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
10 aug 2006 - 11:56
Statutaire naam
Pharming Group N.V.
Titel
PHARMING TO PROCEED WITH THE ACQUISITION OF DNAGE
Bericht
Leiden, The Netherlands, August 10, 2006. Biotech company Pharming Group NV (“Pharming”) (Euronext: PHARM) (PHARM.AS) today announced that it will proceed with the acquisition of DNage BV (“DNage”) based on the decision by the Enterprise Section of the Amsterdam Court of Appeal (“Enterprise Section”).
The Enterprise Section has rejected the appeal of the Works Council regarding the proposed acquisition of DNage. The decision allows Pharming to proceed with the acquisition, which will now be finalized as originally planned. Pharming expects the legal agreements and other formalities necessary for the acquisition to be completed in the near future.
On March 24, 2006, Pharming announced a heads of agreement with DNage to acquire all shares of DNage. During the acquisition process, the Works Council of Pharming provided a negative advice on the acquisition. The Works Council appealed the decision of the Board of Management of Pharming to acquire DNage at the Enterprise Section.
“Pharming is excited to proceed with the acquisition of DNage,” said Dr. Francis Pinto, Chief Executive Officer of Pharming. “Through DNage, Pharming will gain access to a highly innovative technology platform and products for several new markets such as metabolic diseases, like type II diabetes and genetic diseases, such as premature ageing.”
Datum laatste update: 16 december 2025